A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)

on behalf of Hokkaido Lung Cancer Clinical Study Group

Research output: Contribution to journalArticle

8 Citations (Scopus)

Fingerprint Dive into the research topics of 'A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences